- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06212583
High-Risk Metachronous Oligometastatic Prostate Cancer Trial (KNIGHTS)
A Randomized Trial of High-risK metachroNous oligometastatIc Prostate Cancer With hiGh-risk Mutations Treated witH meTastasiS Directed Therapy and Niraparib/Abiraterone Acetate and Prednisone (KNIGHTS)
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Caitlin Eggleston
- Phone Number: 410-328-7586
- Email: caitlineggleston@umm.edu
Study Contact Backup
- Name: Phuoc Tran, MD
- Phone Number: 410-328-6080
- Email: phuoc.tran@umm.edu
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21201
- Recruiting
- University of Maryland Greenebaum Cancer Center
-
Contact:
- Phuoc Tran, MD
- Phone Number: 410-328-6080
-
Contact:
- Caitlin Eggleston
- Phone Number: 410-328-7586
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- ≥18 years of age (or the local legal age of consent).
Patient must have at least one and up to three asymptomatic metastatic tumor(s) of the bone, soft tissue, or extra-pelvic nodal region each < 5 cm or < 250 cm3 that develop within the past 6-months that are seen on imaging. A nodal lesion is defined to include nodal conglomerates located in the same nodal chain such that they can be treated in one SABR field. Up to five lesions are allowed on advanced functional imaging such as fluciclovine (Axumin), choline or Prostate Specific Membrane Antigen (PSMA) PET-CT scan.
- CT or MRI scan within 6 months of enrollment
- Bone scan within 6 months of enrollment
- Fluciclovine (Axumin), choline, or PSMA PET-CT scan within 6 months of enrollment (PET-CT scan is reasonable for study entry imaging as an alternative to CT/MRI scan and bone scan)
- Must have a high-risk pathogenic mutation (TP53, BRCA1/2, PALB2, ATM, BRIP1, CHEK2, FANCA, RAD51B, RAD54L, MUTYH) by next generation sequencing. ATM mutation enrollment will be capped at 5% of the overall population.
- Histologic confirmation of prostate adenocarcinoma (primary or metastatic tumor).
- Patient may have had prior systemic therapy and/or ADT so long as testosterone is > 100 ng/dl prior to enrollment
- PSA > 0.5 but <50 at enrollment.
- Prostate Specific Antigen Doubling Time (PSADT) < 15 months
- Baseline testosterone > 100 ng/dl
- Patient must have a life expectancy ≥ 12 months.
- Patient must have an ECOG performance status ≤ 2.
Adequate hematologic, renal, and hepatic function at screening defined as follows:
• Absolute neutrophil count ≥1.5 x 109/L
• Hemoglobin ≥9.0 g/dL, independent of transfusions for at least 28 days
- Platelet count ≥100 x 109/L
- Creatinine <2 x upper limit of normal (ULN)
- Serum potassium ≥3.5 mmol/L
- Serum total bilirubin ≤1.5× ULN or direct bilirubin ≤1 x ULN (Note: In participants with Gilbert's syndrome, if total bilirubin is >1.5 × ULN, measure direct and indirect bilirubin, and if direct bilirubin is ≤1.5 × ULN, participant may be eligible)
- AST or ALT ≤3 × ULN
- Patient must have the ability to understand and the willingness to sign a written informed consent document
- Able to swallow the study medication tablets whole.
- While on study medication and for 4 months following the last dose of study medication, a male participant must agree to use condom and an adequate contraception method for female partner (WOCBP) A male participant must agree not to donate sperm while on study treatment and for a minimum of 4 months following the last dose of study medication.
- Castration-resistant prostate cancer (CRPC).
- Prior radiation therapy to an overlapping site of a target lesion that would preclude further radiation therapy
- Spinal cord compression or impending spinal cord compression.
- Suspected intracranial and/or liver metastases (>10 mm in largest axis).
- Patient receiving any other investigational agents.
- Inability to receive any form of systemic therapy in the opinion of a treating medical oncologist.
- Unable to lie flat during or tolerate PET/MRI, PET/CT or SABR.
- Radiographical evidence of cranial parenchymal metastasis.
- Active second primary malignancy; AML/MDS in medical history.
- Uncontrolled hypertension and myocardial infarction/PE/cardiac failure in last 6 months.
- Prior treatment with PARP inhibitor
- Refusal to sign informed consent.
- Pathological finding consistent with small cell or neuroendocrine carcinoma of the prostate.
- History of adrenal dysfunction
- Long-term use of systemically administered corticosteroids (>5mg of prednisone or the equivalent) during the study is not allowed. Short-term use (≤4 weeks, including taper) and locally administered steroids (eg, inhaled, topical, ophthalmic, and intra-articular) are allowed, if clinically indicated.
Active malignancies (ie, progressing or requiring treatment change in the last 24 months) other than the disease being treated under study. The only allowed exceptions are:
- non-muscle invasive bladder cancer.
- skin cancer (non-melanoma or melanoma) treated within the last 24 months that is considered completely cured.
- malignancy that is considered cured with minimal risk of recurrence.
- History or current diagnosis of MDS/AML.
Current evidence within 6 months prior to randomization of any of the following:
• severe/unstable angina, myocardial infarction, symptomatic congestive heart failure,
• clinically significant arterial or venous thromboembolic events (ie. Pulmonary embolism), or clinically significant ventricular arrhythmias.
- Presence of sustained uncontrolled hypertension (systolic blood pressure >160 mm Hg or diastolic blood pressure >100 mm Hg). Participants with a history of hypertension are allowed, provided that blood pressure is controlled to within these limits by an antihypertensive treatment.
- Known allergies, hypersensitivity, or intolerance to the excipients of niraparib/abiraterone acetate tablets
- Current evidence of any medical condition that would make prednisone use contraindicated.
- Received an investigational intervention (including investigational vaccines) or used an invasive investigational medical device within 30 days before the planned first dose of study medication.
Participants who have had the following ≤28 days prior to randomization:
• A transfusion (platelets or red blood cells);
• Hematopoietic growth factors;
• Major surgery
Human immunodeficiency virus positive participants with 1 or more of the following:
• Not receiving highly active antiretroviral therapy or on antiretroviral therapy for less than 4 weeks.
- Receiving antiretroviral therapy that may interfere with the study medication
- CD4 count <350 at screening.
- An acquired immunodeficiency syndrome-defining opportunistic infection within 6 months of the start of screening.
- Human immunodeficiency virus load >400 copies/mL
- Active or symptomatic viral hepatitis or chronic liver disease; encephalopathy, ascites or bleeding disorders secondary to hepatic dysfunction.
- Moderate or severe hepatic impairment (Class B and C per Child-Pugh classification system.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Androgen deprivation therapy + Stereotactic ablative radiation
|
Both arms will receive SABR
All ADT is provided as best prescribed for patient per their medical oncologist.
|
Active Comparator: Androgen deprivation therapy + Stereotactic ablative radiation + niraparib/abiraterone acetate
|
Both arms will receive SABR
All ADT is provided as best prescribed for patient per their medical oncologist.
Patients on Arm 2 to receive drug for 6 months
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PSA (Prostate Specific Antigen) evaluation at the 18-month progression of both treatment arms
Time Frame: 18 months
|
PSA evaluation of progression at 18-month PSA , defined as PSA > 0.2 ng/mL in patients initially treated with radical prostatectomy and greater than nadir + 2 ng/mL for patients initially treated with definitive radiation, with testosterone >100 ng/dl of men who have oligometastatic castration-sensitive prostate cancer with high-risk mutations (TP53, BRCA1/2, PALB2, ATM, BRIP1, CHEK2, FANCA, RAD51B, RAD54L, MUTYH) treated with ADT + SABR MDT (6-mos) versus ADT + SABR MDT + niraparib/abiraterone acetate and prednisone (6-mos).
|
18 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment-related adverse events of both treatment arms
Time Frame: 4 years
|
Number of participants with treatment-related adverse events from ADT+ SABR MDT (6-mos) vs ADT + SABR MDT + niraparib/abiraterone acetate and prednisone (6-mos) in patients with metachronous oligometastatic CSPC disease.
|
4 years
|
Time to locoregional progression, time to distant progression, time to new metastasis, radiographic progression-free survival and duration of response after randomization
Time Frame: 4 years
|
Progression will be assessed for time to locoregional progression, time to distant progression, time to new metastasis, radiographic progression-free survival and duration of response after randomization.
|
4 years
|
Quality-of-life measured through EPIC tool following completion of ADT+ SABR MDT (6-mos) vs ADT + SABR MDT + niraparib/abiraterone acetate and prednisone (6-mos).
Time Frame: 4 years
|
EPIC quality of life tool will be used to assess quality of life following treatment.
Averages will be taken for each section in the survey (Urinary Function, Bowel Function, Sexual Function, and Hormonal function).
|
4 years
|
Local control at 18 months after ADT+ SABR MDT (6-mos) vs ADT + SABR MDT + niraparib/abiraterone acetate and prednisone (6-mos) in patients with metachronous oligometastatic Castrate Specific Prostate Cancer (CSPC) disease.
Time Frame: 18 months
|
Local control will be evaluated through clinical assessment and periodic imaging.
|
18 months
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Genital Neoplasms, Male
- Prostatic Diseases
- Urogenital Diseases
- Male Urogenital Diseases
- Genital Diseases, Male
- Genital Diseases
- Prostatic Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Poly(ADP-ribose) Polymerase Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Hormone Antagonists
- Steroid Synthesis Inhibitors
- Niraparib
- Abiraterone Acetate
- Androgens
Other Study ID Numbers
- HP-00108148
- GCC 23100 (Other Identifier: University of Maryland Medical System)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer
-
Roswell Park Cancer InstituteRecruitingObesity | Overweight | Cancer Survivor | Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage A Prostate Cancer | Stage... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Regeneron Pharmaceuticals; Prostate Cancer FoundationWithdrawnStage III Prostate Cancer | Stage IV Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage IIIA Prostate Cancer | Stage IIIB Prostate Cancer | Stage IIIC Prostate Cancer
-
University of Southern CaliforniaNational Cancer Institute (NCI); SanofiTerminatedDiarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ryan Kohlbrenner, MDRadiological Society of North AmericaCompletedProstate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage...United States
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.TerminatedRandomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...United States
-
Ohio State University Comprehensive Cancer CenterRiverside Methodist HospitalCompletedStage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
University of California, IrvineCompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
NRG OncologyNational Cancer Institute (NCI)RecruitingProstate Adenocarcinoma | Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer... and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate...United States
Clinical Trials on Stereotactic ablative radiation therapy (SABR)
-
University of Texas Southwestern Medical CenterActive, not recruitingRenal CancersUnited States
-
Indiana UniversityIndiana University School of MedicineWithdrawn
-
University of Maryland, BaltimoreRecruitingProstate Cancer | Oligometastatic DiseaseUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); Cancer Prevention Research Institute of TexasActive, not recruitingMetastatic Renal Cell Carcinoma | Stage IV Renal Cell Cancer AJCC v8 | Malignant Neoplasms of Urinary Tract | Oligometastatic Renal Cell CarcinomaUnited States
-
Luhua WangUnknownNon-Small Cell Lung CancerChina
-
Radiation Therapy Oncology GroupNational Cancer Institute (NCI); NRG OncologyCompleted
-
University of Texas Southwestern Medical CenterActive, not recruiting
-
Indiana UniversityIndiana University School of MedicineTerminatedLung CancerUnited States
-
University of Texas Southwestern Medical CenterActive, not recruiting
-
University of California, San FranciscoJanssen PharmaceuticalsActive, not recruitingCastration-Resistant Prostate Carcinoma | PSA Progression | Stage IV Prostate Adenocarcinoma AJCC v7 | Castration Levels of TestosteroneUnited States